This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
A 16-amino acid peptide encoded in the mitochondrial genome — not the nuclear genome. Activates AMPK, the master regulator of cellular energy, to improve insulin sensitivity, metabolic flexibility, and stress resilience. One of the most researched mitochondrial-derived peptides in longevity science.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is encoded in the mitochondrial genome — a discovery that upended the assumption that mitochondria only produce energy. Published by Dr. Pinchas Cohen's lab at USC in Cell Metabolism (2015), MOTS-c was the first mitochondrial-derived peptide (MDP) shown to have hormone-like systemic effects when released into circulation.
Under metabolic stress — exercise, fasting, caloric restriction — MOTS-c is released from mitochondria, enters the bloodstream, and translocates to the nucleus where it activates AMPK signaling pathways. The effect mimics the metabolic benefits of exercise at a cellular level: improved glucose uptake, enhanced fat oxidation, better insulin sensitivity, and increased stress resilience.
MOTS-c levels naturally decline with age — parallel to the decline in mitochondrial function that underlies much of the aging phenotype. Research in aged mice shows MOTS-c supplementation reverses age-related insulin resistance and restores metabolic flexibility to younger-state parameters.
MOTS-c directly activates AMPK — the cellular energy sensor that signals low-energy states. AMPK activation improves glucose uptake, inhibits fatty acid synthesis, and enhances mitochondrial biogenesis.
In mouse models of diet-induced obesity and diabetes, MOTS-c restored insulin sensitivity and reduced blood glucose. Mechanism involves improved GLUT4 translocation and reduced inflammatory signaling in adipose and muscle tissue.
MOTS-c levels rise in circulation during exercise. Research suggests it mediates some of exercise's metabolic benefits — making it a subject of study in contexts where exercise capacity is limited.
In aged mice, MOTS-c extended median lifespan and improved several hallmarks of aging — metabolic flexibility, physical performance, and inflammatory markers — when administered in late life.
AMPK activation shifts cellular metabolism toward fat oxidation as a fuel source. MOTS-c is studied for body composition effects, particularly in the context of age-related fat accumulation and metabolic syndrome.
MOTS-c is a retrograde signal — mitochondria release it when under stress to coordinate a whole-cell and whole-body adaptive response. It upregulates stress-response genes and improves cellular resilience.
Human clinical data on MOTS-c dosing is still early-stage. The following is extrapolated from rodent studies (scaled to human equivalent) and researcher community protocols. Start at the lower end and assess response.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Standard | 5–10mg SC | Daily or 5x/week | Most research protocols use daily dosing. Morning administration before food aligns with natural endogenous release patterns during fasting states. |
| Higher dose | 10mg SC | Daily | Upper range used in longer-term research protocols. No established maximum; human safety data limited to early-phase research. |
| Cycle length | — | 4–8 weeks on, 4 weeks off | Cycling is common practice given limited long-term human data. Some researchers run continuously; risk profile is not well characterized beyond 12 weeks. |
Skeletal muscle MOTS-c concentration increases 11.9-fold following exercise, with a 1.6-fold rise in blood circulation. This makes MOTS-c one of the most exercise-responsive signaling peptides identified to date. (Zheng et al., Frontiers in Endocrinology, 2023)
Blood MOTS-c levels in young people are 11% higher than in middle-aged individuals and 21% higher than in the elderly. This age-related decline closely tracks the broader deterioration of mitochondrial function that underlies the aging phenotype.
In aged mice, MOTS-c intervention improved age-related insulin resistance within 7 days — a notably rapid metabolic response that positions it as a candidate for acute metabolic support.
Obese children showed significantly lower intra-cycle MOTS-c levels — 20.3% below lean controls. Lower endogenous MOTS-c may both result from and contribute to metabolic dysfunction, suggesting a reinforcing cycle that exogenous MOTS-c may interrupt.
MOTS-c is prohibited by the World Anti-Doping Agency (WADA) under Section S4 of the Prohibited List, classified as an AMPK pathway activator and metabolic modulator. USADA has issued formal guidance warning competitive athletes against its use. No Therapeutic Use Exemption is available because no approved medical indication exists.
This classification reflects WADA's assessment that MOTS-c confers a meaningful metabolic advantage — which is, for a non-athlete patient population pursuing metabolic health, longevity, and recovery goals, a signal worth noting. Regulators prohibit substances they believe work. Cinch Bio's protocols are designed exclusively for non-athlete patients under physician supervision; competitive athletes should consult their sport's governing body before using any peptide protocol.
MOTS-c has no completed human clinical trials, which means its safety profile is characterized primarily by rodent research and researcher community reports rather than controlled human data. The following effects have been reported by research users and documented in adverse event reporting contexts:
The most commonly reported effect — mild redness, swelling, or tenderness at the SC injection site. Typically resolves within hours. Rotating injection sites reduces incidence.
Some users report transient elevation in resting heart rate, likely related to AMPK activation and its downstream metabolic effects. Usually mild and self-limiting. Monitor if you have pre-existing cardiovascular conditions.
Insomnia and altered sleep patterns reported by a subset of users. Administering MOTS-c in the morning rather than evening may reduce this. The mechanism is unclear but may relate to metabolic activation.
Low-grade fever reported in some users, particularly at higher doses. This may represent an immune-modulatory response. If fever is sustained or high-grade, discontinue and consult your physician.
Long-term safety data beyond 12 weeks in humans does not exist. MOTS-c is a research-stage peptide. The absence of reported serious adverse events in the research community is encouraging, but is not equivalent to a proven safety record.
MOTS-c pairs well with other longevity and metabolic support peptides. Complementary mechanisms rather than overlapping targets:
Third-party COA, Finnrick-verified purity, lyophilized for long-term stability. Ships within 24 hours.
Start Protocol Intake ← All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.